Fang Shu, Wang Zhehai
School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Shandong Cancer Hospital, Jinan, Shandong Province, People's Republic of China.
Department of Oncology, Shandong Cancer Hospital, Jinan, Shandong Province, People's Republic of China.
Drug Des Devel Ther. 2014 Sep 26;8:1595-611. doi: 10.2147/DDDT.S69690. eCollection 2014.
Non-small-cell lung cancer (NSCLC) has entered the age of individual treatment, and increasing point mutations of specific oncogenes and rearrangement of some chromosomes are biomarkers used to predict the therapeutic effect of targeted therapy. At present, there is a consensus among clinicians that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown favorable efficacy in NSCLC patients with EGFR mutation, and some relevant research has suggested that the presence of EGFR mutations is a favorable prognostic marker. However, the association of EGFR mutation status with the responsiveness to conventional chemotherapy agents and survival in NSCLC patients is still unclear. This review provides an overview of and assesses the role of EGFR as a prognostic marker for postoperative patients and as a predictive marker for response to cytotoxic chemotherapy. In addition, we review the comparison of response to chemotherapy between EGFR mutations in exon 19 and in exon 21 and the predictive role of p.T790M mutation.
非小细胞肺癌（NSCLC）已进入个体化治疗时代，特定癌基因的点突变增加以及一些染色体重排是用于预测靶向治疗疗效的生物标志物。目前，临床医生已达成共识，即表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）在EGFR突变的NSCLC患者中显示出良好疗效，一些相关研究表明EGFR突变的存在是一个良好的预后标志物。然而，EGFR突变状态与NSCLC患者对传统化疗药物的反应性及生存的相关性仍不明确。本综述概述并评估了EGFR作为术后患者预后标志物以及作为细胞毒性化疗反应预测标志物的作用。此外，我们还综述了外显子19和外显子21中EGFR突变对化疗反应的比较以及p.T790M突变的预测作用。
